Checchi Capital Advisers LLC increased its Pfizer stake by 3.4% in the second quarter, acquiring 1,159 more shares and bringing its total holdings to 35,224. The disclosure was released in a filing with the Securities and Exchange Commission, highlighting continued investor interest in one of the world’s largest pharmaceutical companies.

Penobscot Investment Management Company Inc. has reduced its position in Pfizer Inc. by 9.5% in the second quarter. According to the latest SEC filing, the institutional investor sold 9,075 Pfizer shares, leaving the firm with 86,226 shares of the prominent biopharmaceutical company.

Pfizer made headlines by forging a drug pricing agreement with the Trump administration, surprising many in the pharmaceutical industry. The move exposed rifts within Big Pharma, as other companies were left scrambling to respond.

In its most recent regulatory filing, USS Investment Management Ltd disclosed a significant reduction in its holdings of Pfizer Inc. Selling over one million shares during the first quarter, the fund reduced its Pfizer stake by more than half.

Prospector Partners LLC has sharply increased its exposure to Pfizer Inc., buying nearly 54,000 additional shares in the first quarter, according to a recent regulatory filing. The purchase lifts the fund’s stake by 60.9 percent to 142,455 shares, now valued at about $3.61 million.